SlideShare a Scribd company logo
1 of 44
Hypertension
UTTARA L. JOSHI
Normal BP: <120/<80
Prehypertension: 120-139/80-89
Hypertension stage1 140-159/90-99
Hypertension stage 2 160/100
Emergency >210/>120
Resistant hypertension Failure of BP
control with
three drug
regimen
Isolated systolic >140/<90
hypertension
How can we treat hypertension
•Secondary hypertension- treat underlying cause
•Essential hypertension- cause not known
•Factors involved- stress, weight, dietary habits, salt retention,
increased angiotensin production, , increased sympathetic tone
•Approaches-
Reduce salt/water content of body
Reduce sympathetic tone
Reduce effects of circulating angiotensin II
Reduce cardiac force of contraction
Dilate peripheral vessels to reduce cardiac filling & consequent
stroke volume
Drugs used for treatment of hypertension:
•Diuretics
•Centrally acting agents- methyl dopa, clonidine
•-Adrenoceptor blockers
•-Adrenoceptor blockers
•Combined  and  blockers
•ACE inhibitors
•ARBs
•CCBs
•Vasodilators
Hydralazine, Minoxidil, Diazoxide,
Fenoldopam (arteriolar)
Sodium nitroprusside
(arteriolar + venular)
Need for life-style changes:
•Weight loss/control
•Restricted sodium intake
•Increasing aerobic exercise
•Moderating alcohol consumption
These changes in life-style may be sufficient to
control hypertension in early stage I
They also facilitate pharmacological treatment
Diuretics:
•Thiazides, loop diuretics and K+ sparing diuretics
They are antihypertensive when given alone
Also enhance the efficacy of other antihypertensive
agents
Exact mechanism not known
Initially decrease extracellular volume and enhance Na+
excretion by inhibiting Na+Cl- co-transporter which leads
to  in CO
Long term therapy- CO and extracellular
volume returns to pretreatment value due to
compensatory mechanisms but antihypertensive
effect persists due to decrease in PVR
 in PVR may occur due to direct vasodilatory
effect of thiazides or due to their effect on kidney
Thiazides should be avoided in patients with
concommitant:
•Diabetes mellitus
•Gout
•Hyperlipidaemia
•Renal insufficiency
High efficacy (ceiling) diuretics
•Severe reduction in blood volume & electrolyte
imbalance
•Strong diuretic
•Weak antihypertensive than thiazide diuretics
•Indicated in HT when complicated by
Chronic renal failure
Coexisting CHF
Severe edema due to use of potent vasodilators
Sympatholytic agents:
•Centrally acting:  methyldopa, clonidine
• Adrenoceptor blockers
• Adrenoceptor blockers
•Combined  and  adrenoceptor blockers- labetalol,
carvedilol
Methyldopa:
•It is an analog of DOPA (dihydroxyphenylalanine)
•It is a pro drug- metabolized in brain by L-aromatic
amino acid decarboxylase in adrenergic neurons to 
methyl dopamine and then converted to  methyl
norepinephrine
• Methyl norepinephrine is stored in the vesicles in place
of NE and released in response to stimulus
•Acts in the CNS to reduce sympathetic outflow from
brain stem
•Also, probably acts an an agonist of central
presynaptic 2 receptors to reduce central
sympathetic outflow
•Rapidly absorbed, t½ approximately 2 h
•Even after i.v. injection effects starts after a
delay of about 6-8 h
•Why the delay in action? probably due to time taken for
transportation to brain and conversion to methyl NE
•ADRs:
Sedation, transient
Dryness of mouth
Parkinsonian signs
Hyperprolactenemia leading to gynecomastia or
galactorrhoea
Clonidine, Guanbenz and Guanfacine:
•Stimulate 2A subtype of 2 receptors in the brain stem
and reduce the central sympathetic outflow
• in plasma concentration of NE correlates with the
decrease in BP
•Decreased sympathetic outflow also reduces cardiac
output & HR
•In supine position, when the sympathetic tone to
vasculature is low, the effect is mainly by reducing HR
and stroke volume
•In upright position, the vasculature tone is high
and effect is mainly by reducing the PVR
•Since they block peripheral vasoconstriction,
postural hypotension may occur
ADRs:
•Sedation
•Xerostomia
•Dryness of eye, nasal mucosa
•Parotid swelling
•Postural hypotension
•Erectile dysfunction
•Bradycardia, sinus arrest, AV block
•Rebound hypertension
Guanadrel:
•Exogenous false neurotransmitter
•Actively transported to adrenergic neuron by NET (NE
transporter)
•Previously NET was known as Uptake 1
•Stored in adrenergic neurons where it is concentrated in
storage vesicles and replaces NE
•Released in place of NE and acts as false neurotransmitter
•It has no activity on adrenergic receptors
•This inhibits the functioning of peripheral
adrenergic neurons
•Antihypertensive effect is achieved by
reduction in PVR
•Postural hypotension
-Adrenergic blockers:
•Decrease HR, output and stroke volume (1)
•Inhibit renin release from JG apparatus (1)
•Block -receptors of peripheral blood vessels so they
constrict (2)
•PVR increases initially but gradually returns to
pretreatment values or less
•Those crossing the BBB also reduce central sympathetic
tone
•Do not cause retention of salt and water
•Often combined with diuretics- additive effect
•Highly preferred drugs for hypertensive
patients with complications like angina, MI or
CHF
-Adrenoceptor blockers produce:
•Decreased myocardial contraction & cardiac output
(1)
•Decreased renin secretion (1)
•Decreased central sympathetic activity (Presynaptic 2
effect)
All -adrenoceptor blockers produce:
•Reduced exercise tolerance
•Mild chronic fatigue
•Sedation
•Increased airway resistance
•Bradycardia
•Sleep disturbances-  melatonin release
•All -adrenoceptor blockers initially produce
vasoconstriction by blocking vascular -receptors that
relax vascular smooth muscles
•This vasoconstriction disappears after some time
(adaptability ?)
-Adrenoceptor blockers with intrinsic
sympathomimetic activity:
Advantages:
•Less bradycardia & myocardial suppression-
useful in patients having low cardiac reserve
•Less likely rebound hypertension
•Less worsening of lipid profile
•Less effect on exercise tolerance
β-Adrenoceptor blockers with intrinsic activity:
• Oxeprenolol
• Pindolol
• Penbutolol
• Acebutolol
Nebivolol: 1 selective antagonist
•Promotes vasodilation due to  production of
NO in arterial smooth muscle
•Has antioxidant properties also
1-Adrenoceptor blockers:
•Block 1-adrenoceptors on smooth muscles of
arterioles
•Reduce arteriolar resistance and increase venous
capacitance
•Reflex increase in HR and plasma renin activity
•Return to normal during long term therapy
•Postural hypotension may occur depending on plasma
volume
•Reduce total plasma concentration of
triglycerides and LDL
•Increase plasma levels of HDL- beneficial
effect
•Effect on lipids persists even when combined
with diuretics
•Preferred in hypertensive patients with BPH
Combined  and  adrenoceptor blockers:
•Labetalol and carvedilol
•Labetalol is a mixture of four stereoisomers- one
isomer is  blocker like prazosin, another is a non-
selective  blocker with partial agonist activity like
pindolol
•Other two isomers are inactive
•Carvedilol is a  receptor antagonist with 1 receptor
blocking activity
•Pheochromocytoma
Vasodilators: Hydralazine:
Directly relaxes the arteriolar smooth muscle
Mechanism uncertain
Does not relax venous smooth muscle
Compensatory reflex increase in sympathetic outflow
Increase in HR, cardiac output, plasma renin activity and
fluid retention
Selective decrease in vascular resistance in coronary,
cerebral and renal vascular beds
Postural hypotension- uncommon because it does not
dilate veins
ADRs:
•Extension of pharmacological effects: headache,
flushing, hypotension, palpitation, tachycardia,
dizziness, nausea
•Can precipitate angina or MI due to increased
myocardial O2 demand
•Immunological reactions- drug induced lupus
syndrome, serum sickness, hemolytic anemia
•Pyridoxine responsive polyneuropathy- probably
because hydralazine combines with pyridoxine to form
hydrazone
Minoxidil:
•Converted in liver to active form- minoxidil N-O sulphate
•Produces arteriolar vasodilation
•No effect on venous capacitance vessels
•Causes increase in cardiac output
•Blood flow to skin, skeletal muscles, GIT and heart is
increased
•Dilates renal artery, nett effect depends on hypotension
and extent of dilatation
•Potent stimulator of renin secretion- by
increasing sympathetic outflow and effecting
renal regulation of renin release
•Minoxidil sulphate opens ATP-modulated K+
channels
•K+ efflux occurs, cell is hyperpolarized
May precipitate severe bradycardia/sinus arrest
Hepatotoxicity- Coombs test (antiglobulin)
necessary because autoantibodies are produced
against Rh antigen
Preferred drug for treatment of hypertension
during pregnancy
ADRs:
•CVS: same as hydralazine
•Hypertrichosis: (abnormal hair growth in the
body) may occur
Uses:
•Severe hypertension- should never be given
alone; always with a diuretic to prevent fluid
retention and a sympatholytic drug to control
reflex CVS changes
•Baldness- topical
Diazoxide:
•Chemically related to thiazide diuretics but has no diuretic
activity
•Instead causes retention of sodium and water
•Acts by opening K+ channels in arteriolar smooth muscle
cells
•No effect on venules
•Causes hyperglycemia
•Used for short term treatment of hypertensive
emergencies
•Often combined with a diuretic and a  blocker
Fenoldopam:
•Agonist of dopamine D1 receptors
•Causes dilatation of arterioles and natriuresis
•Oral bioavailability is poor
•t½ approx. 5 min
•Onset of action is rapid
•Increases renal output, creatinine clearance and sodium
excretion so concomitant use of diuretic or  blocker is not
required
•ADRs: reflex tachycardia, headache, flushing
•Increases intraocular pressure so should be avoided in
glaucoma
Sodium nitroprusside:
•Releases NO which dilates the blood vessels
•Mechanism of NO release not known but mimics
endogenous NO release by vascular endothelial cells
•No development of tolerance (it occurs to nitroglycerine)
•Dilates both arterioles and venules
•CO falls due to venous pooling and reduction in PVR
•Plasma renin activity increases
•Unlike arteriolar dilators hydralazine, minoxidil and
diazoxide, it causes only modest increase in HR and
reduces cardiac O2 demand
•Used to treat hypertensive emergencies,
aortic dissection, controlled hypotension
during anesthesia
•Effect of light on drug
Toxicity:
•Headache, nausea, vomiting-disappear after the drug is
discontinued
•Cyanide or thiocyanate accumulation
•Thiocyanate toxicity- psychosis, disorientation and
convulsions
•Methemoglobinaemia- due to cyanide
•Administration of sodium thiosulfate and
hydroxycobalamine
•Sodium thiosulfate- acts as a sulfur donor and facilitates
metabolism of thiocyanates
•Hydrocobalamine- combines with cyanide ion to form
non-toxic cyanocobalamine
Pregnancy
•If taken before pregnancy, most anti-HTN can be
continued except ACE inhibitors and angiotensin II
receptor blockers.
•Methyldopa is most widely used for hypertension during
pregnancy.
•Beta-blockers are not recommended early in pregnancy.
Drugs to be avoided for treatment of hypertension
associated with other diseases:
Pregnancy ACEI, ARBs, -blockers,
diuretics
Diabetes mellitus IIDDM) Diuretics, -blockers
Angina pectoris Vasodilators
Bronchial asthma -blockers
Peripheral vascular disease -blockers
CHF CCBs except amlodipine,
 and -blockers
C) hypertension

More Related Content

What's hot (20)

Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
Hypertension Hypertension
Hypertension
 
Phamacological Management of Essential Hypertension - Revision Guide
Phamacological Management of Essential Hypertension - Revision GuidePhamacological Management of Essential Hypertension - Revision Guide
Phamacological Management of Essential Hypertension - Revision Guide
 
Hypertension
HypertensionHypertension
Hypertension
 
Pharmacotherapy of hypertension
Pharmacotherapy of hypertensionPharmacotherapy of hypertension
Pharmacotherapy of hypertension
 
Hypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood PressureHypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood Pressure
 
Hypertension
HypertensionHypertension
Hypertension
 
Severe HTN ( hypertention) فشار خون بالا
Severe HTN ( hypertention) فشار خون بالاSevere HTN ( hypertention) فشار خون بالا
Severe HTN ( hypertention) فشار خون بالا
 
Pharmacotherapy of hypertension
Pharmacotherapy of hypertensionPharmacotherapy of hypertension
Pharmacotherapy of hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Pathology of Hypertension
Pathology of HypertensionPathology of Hypertension
Pathology of Hypertension
 
Hypertension 2012
Hypertension 2012Hypertension 2012
Hypertension 2012
 
Hypertension basics 2014
Hypertension basics 2014Hypertension basics 2014
Hypertension basics 2014
 
Hypertension lecture
Hypertension lecture Hypertension lecture
Hypertension lecture
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Diagnostic evaluation of HTN
Diagnostic evaluation of HTNDiagnostic evaluation of HTN
Diagnostic evaluation of HTN
 
Hypertension pathophysiology
Hypertension   pathophysiologyHypertension   pathophysiology
Hypertension pathophysiology
 
hypertension, CCF
hypertension, CCFhypertension, CCF
hypertension, CCF
 
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
 

Similar to C) hypertension

Hypertension.ppt شه شی دی
Hypertension.ppt شه شی دی Hypertension.ppt شه شی دی
Hypertension.ppt شه شی دی ssuserddee4d
 
Hypertension.ppt
Hypertension.pptHypertension.ppt
Hypertension.pptSheik4
 
Hypertension.ppt
Hypertension.pptHypertension.ppt
Hypertension.pptImtiyaz60
 
Pharmacology_of_HTN_for_midwife[1].pptx
Pharmacology_of_HTN_for_midwife[1].pptxPharmacology_of_HTN_for_midwife[1].pptx
Pharmacology_of_HTN_for_midwife[1].pptxwakogeleta
 
CV for undergraduate nurse.pptx
CV for undergraduate nurse.pptxCV for undergraduate nurse.pptx
CV for undergraduate nurse.pptxwakogeleta
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.pptSheik4
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.pptImtiyaz60
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.pptImtiyaz60
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.pptTaslimKaba1
 
Pharmacotherapy, Management of Hypertension, JNC 8 guidelines
Pharmacotherapy, Management of Hypertension, JNC 8 guidelinesPharmacotherapy, Management of Hypertension, JNC 8 guidelines
Pharmacotherapy, Management of Hypertension, JNC 8 guidelinesankitamishra1402
 
Anti hypertensives
Anti hypertensivesAnti hypertensives
Anti hypertensivesAman Hassan
 
Anti hypertensives
Anti hypertensivesAnti hypertensives
Anti hypertensivesAman Hassan
 

Similar to C) hypertension (20)

Hypertension.ppt شه شی دی
Hypertension.ppt شه شی دی Hypertension.ppt شه شی دی
Hypertension.ppt شه شی دی
 
Hypertension.ppt
Hypertension.pptHypertension.ppt
Hypertension.ppt
 
Hypertension.ppt
Hypertension.pptHypertension.ppt
Hypertension.ppt
 
Hypertension.ppt
Hypertension.pptHypertension.ppt
Hypertension.ppt
 
Hypertension (5).ppt
Hypertension (5).pptHypertension (5).ppt
Hypertension (5).ppt
 
Hypertension.ppt
Hypertension.pptHypertension.ppt
Hypertension.ppt
 
Pharmacology_of_HTN_for_midwife[1].pptx
Pharmacology_of_HTN_for_midwife[1].pptxPharmacology_of_HTN_for_midwife[1].pptx
Pharmacology_of_HTN_for_midwife[1].pptx
 
CV for undergraduate nurse.pptx
CV for undergraduate nurse.pptxCV for undergraduate nurse.pptx
CV for undergraduate nurse.pptx
 
antihypertensive drugs
antihypertensive drugsantihypertensive drugs
antihypertensive drugs
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
 
Heart Failure.ppt
Heart Failure.pptHeart Failure.ppt
Heart Failure.ppt
 
Pharmacotherapy, Management of Hypertension, JNC 8 guidelines
Pharmacotherapy, Management of Hypertension, JNC 8 guidelinesPharmacotherapy, Management of Hypertension, JNC 8 guidelines
Pharmacotherapy, Management of Hypertension, JNC 8 guidelines
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Anti hypertensives
Anti hypertensivesAnti hypertensives
Anti hypertensives
 
Anti hypertensives
Anti hypertensivesAnti hypertensives
Anti hypertensives
 
Vasoactive and inotropic agents
Vasoactive and inotropic agentsVasoactive and inotropic agents
Vasoactive and inotropic agents
 

More from Uttara Joshi

2nd year anti-anginal_drugs
2nd year anti-anginal_drugs2nd year anti-anginal_drugs
2nd year anti-anginal_drugsUttara Joshi
 
A) hemodynamics cardiotonics
A) hemodynamics cardiotonicsA) hemodynamics cardiotonics
A) hemodynamics cardiotonicsUttara Joshi
 
general anaesthesia
general anaesthesia general anaesthesia
general anaesthesia Uttara Joshi
 
Antimalarialdrugs 121209052634-phpapp02
Antimalarialdrugs 121209052634-phpapp02Antimalarialdrugs 121209052634-phpapp02
Antimalarialdrugs 121209052634-phpapp02Uttara Joshi
 
Chapter no 1 poc presentation no 1
Chapter no 1 poc presentation no 1Chapter no 1 poc presentation no 1
Chapter no 1 poc presentation no 1Uttara Joshi
 
Drugsandmagicremediesact
Drugsandmagicremediesact Drugsandmagicremediesact
Drugsandmagicremediesact Uttara Joshi
 
New presentation for assay technique uttara (1)
New presentation for assay technique uttara (1)New presentation for assay technique uttara (1)
New presentation for assay technique uttara (1)Uttara Joshi
 
Chapter 1 poc presentation no 3
Chapter 1 poc presentation no 3Chapter 1 poc presentation no 3
Chapter 1 poc presentation no 3Uttara Joshi
 
Antituberculardrug 150818191332-lva1-app6892 2
Antituberculardrug 150818191332-lva1-app6892 2Antituberculardrug 150818191332-lva1-app6892 2
Antituberculardrug 150818191332-lva1-app6892 2Uttara Joshi
 
Antilerpoticdrugs 170827172207
Antilerpoticdrugs 170827172207Antilerpoticdrugs 170827172207
Antilerpoticdrugs 170827172207Uttara Joshi
 
Sulphonamides 191117134235
Sulphonamides 191117134235Sulphonamides 191117134235
Sulphonamides 191117134235Uttara Joshi
 
Antisepticanddisinfectant
Antisepticanddisinfectant Antisepticanddisinfectant
Antisepticanddisinfectant Uttara Joshi
 
declaration of helsinki ppt
declaration of helsinki pptdeclaration of helsinki ppt
declaration of helsinki pptUttara Joshi
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and designUttara Joshi
 
screening of antiulcer agents
screening  of antiulcer agentsscreening  of antiulcer agents
screening of antiulcer agentsUttara Joshi
 

More from Uttara Joshi (19)

Amoebics agent
Amoebics agentAmoebics agent
Amoebics agent
 
2nd year anti-anginal_drugs
2nd year anti-anginal_drugs2nd year anti-anginal_drugs
2nd year anti-anginal_drugs
 
Chf new ppt
Chf new pptChf new ppt
Chf new ppt
 
A) hemodynamics cardiotonics
A) hemodynamics cardiotonicsA) hemodynamics cardiotonics
A) hemodynamics cardiotonics
 
transqulizers
transqulizers transqulizers
transqulizers
 
Poison act 1919
Poison act 1919Poison act 1919
Poison act 1919
 
general anaesthesia
general anaesthesia general anaesthesia
general anaesthesia
 
Antimalarialdrugs 121209052634-phpapp02
Antimalarialdrugs 121209052634-phpapp02Antimalarialdrugs 121209052634-phpapp02
Antimalarialdrugs 121209052634-phpapp02
 
Chapter no 1 poc presentation no 1
Chapter no 1 poc presentation no 1Chapter no 1 poc presentation no 1
Chapter no 1 poc presentation no 1
 
Drugsandmagicremediesact
Drugsandmagicremediesact Drugsandmagicremediesact
Drugsandmagicremediesact
 
New presentation for assay technique uttara (1)
New presentation for assay technique uttara (1)New presentation for assay technique uttara (1)
New presentation for assay technique uttara (1)
 
Chapter 1 poc presentation no 3
Chapter 1 poc presentation no 3Chapter 1 poc presentation no 3
Chapter 1 poc presentation no 3
 
Antituberculardrug 150818191332-lva1-app6892 2
Antituberculardrug 150818191332-lva1-app6892 2Antituberculardrug 150818191332-lva1-app6892 2
Antituberculardrug 150818191332-lva1-app6892 2
 
Antilerpoticdrugs 170827172207
Antilerpoticdrugs 170827172207Antilerpoticdrugs 170827172207
Antilerpoticdrugs 170827172207
 
Sulphonamides 191117134235
Sulphonamides 191117134235Sulphonamides 191117134235
Sulphonamides 191117134235
 
Antisepticanddisinfectant
Antisepticanddisinfectant Antisepticanddisinfectant
Antisepticanddisinfectant
 
declaration of helsinki ppt
declaration of helsinki pptdeclaration of helsinki ppt
declaration of helsinki ppt
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and design
 
screening of antiulcer agents
screening  of antiulcer agentsscreening  of antiulcer agents
screening of antiulcer agents
 

Recently uploaded

Natural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsNatural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsAArockiyaNisha
 
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxPhysiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxAArockiyaNisha
 
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.aasikanpl
 
zoogeography of pakistan.pptx fauna of Pakistan
zoogeography of pakistan.pptx fauna of Pakistanzoogeography of pakistan.pptx fauna of Pakistan
zoogeography of pakistan.pptx fauna of Pakistanzohaibmir069
 
Analytical Profile of Coleus Forskohlii | Forskolin .pdf
Analytical Profile of Coleus Forskohlii | Forskolin .pdfAnalytical Profile of Coleus Forskohlii | Forskolin .pdf
Analytical Profile of Coleus Forskohlii | Forskolin .pdfSwapnil Therkar
 
Luciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxLuciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxAleenaTreesaSaji
 
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...Lokesh Kothari
 
Cultivation of KODO MILLET . made by Ghanshyam pptx
Cultivation of KODO MILLET . made by Ghanshyam pptxCultivation of KODO MILLET . made by Ghanshyam pptx
Cultivation of KODO MILLET . made by Ghanshyam pptxpradhanghanshyam7136
 
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCESTERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCEPRINCE C P
 
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...Sérgio Sacani
 
Biopesticide (2).pptx .This slides helps to know the different types of biop...
Biopesticide (2).pptx  .This slides helps to know the different types of biop...Biopesticide (2).pptx  .This slides helps to know the different types of biop...
Biopesticide (2).pptx .This slides helps to know the different types of biop...RohitNehra6
 
Artificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C PArtificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C PPRINCE C P
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​kaibalyasahoo82800
 
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Sérgio Sacani
 
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |aasikanpl
 
Bentham & Hooker's Classification. along with the merits and demerits of the ...
Bentham & Hooker's Classification. along with the merits and demerits of the ...Bentham & Hooker's Classification. along with the merits and demerits of the ...
Bentham & Hooker's Classification. along with the merits and demerits of the ...Nistarini College, Purulia (W.B) India
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxAleenaTreesaSaji
 
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...jana861314
 
Spermiogenesis or Spermateleosis or metamorphosis of spermatid
Spermiogenesis or Spermateleosis or metamorphosis of spermatidSpermiogenesis or Spermateleosis or metamorphosis of spermatid
Spermiogenesis or Spermateleosis or metamorphosis of spermatidSarthak Sekhar Mondal
 
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝soniya singh
 

Recently uploaded (20)

Natural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsNatural Polymer Based Nanomaterials
Natural Polymer Based Nanomaterials
 
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxPhysiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
 
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Mayapuri Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
 
zoogeography of pakistan.pptx fauna of Pakistan
zoogeography of pakistan.pptx fauna of Pakistanzoogeography of pakistan.pptx fauna of Pakistan
zoogeography of pakistan.pptx fauna of Pakistan
 
Analytical Profile of Coleus Forskohlii | Forskolin .pdf
Analytical Profile of Coleus Forskohlii | Forskolin .pdfAnalytical Profile of Coleus Forskohlii | Forskolin .pdf
Analytical Profile of Coleus Forskohlii | Forskolin .pdf
 
Luciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxLuciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptx
 
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
 
Cultivation of KODO MILLET . made by Ghanshyam pptx
Cultivation of KODO MILLET . made by Ghanshyam pptxCultivation of KODO MILLET . made by Ghanshyam pptx
Cultivation of KODO MILLET . made by Ghanshyam pptx
 
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCESTERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
STERILITY TESTING OF PHARMACEUTICALS ppt by DR.C.P.PRINCE
 
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
 
Biopesticide (2).pptx .This slides helps to know the different types of biop...
Biopesticide (2).pptx  .This slides helps to know the different types of biop...Biopesticide (2).pptx  .This slides helps to know the different types of biop...
Biopesticide (2).pptx .This slides helps to know the different types of biop...
 
Artificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C PArtificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C P
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​
 
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
Discovery of an Accretion Streamer and a Slow Wide-angle Outflow around FUOri...
 
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
Call Us ≽ 9953322196 ≼ Call Girls In Mukherjee Nagar(Delhi) |
 
Bentham & Hooker's Classification. along with the merits and demerits of the ...
Bentham & Hooker's Classification. along with the merits and demerits of the ...Bentham & Hooker's Classification. along with the merits and demerits of the ...
Bentham & Hooker's Classification. along with the merits and demerits of the ...
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptx
 
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
 
Spermiogenesis or Spermateleosis or metamorphosis of spermatid
Spermiogenesis or Spermateleosis or metamorphosis of spermatidSpermiogenesis or Spermateleosis or metamorphosis of spermatid
Spermiogenesis or Spermateleosis or metamorphosis of spermatid
 
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
Call Girls in Munirka Delhi 💯Call Us 🔝8264348440🔝
 

C) hypertension

  • 2. Normal BP: <120/<80 Prehypertension: 120-139/80-89 Hypertension stage1 140-159/90-99 Hypertension stage 2 160/100 Emergency >210/>120 Resistant hypertension Failure of BP control with three drug regimen Isolated systolic >140/<90 hypertension
  • 3. How can we treat hypertension •Secondary hypertension- treat underlying cause •Essential hypertension- cause not known •Factors involved- stress, weight, dietary habits, salt retention, increased angiotensin production, , increased sympathetic tone •Approaches- Reduce salt/water content of body Reduce sympathetic tone Reduce effects of circulating angiotensin II Reduce cardiac force of contraction Dilate peripheral vessels to reduce cardiac filling & consequent stroke volume
  • 4. Drugs used for treatment of hypertension: •Diuretics •Centrally acting agents- methyl dopa, clonidine •-Adrenoceptor blockers •-Adrenoceptor blockers •Combined  and  blockers •ACE inhibitors •ARBs •CCBs •Vasodilators Hydralazine, Minoxidil, Diazoxide, Fenoldopam (arteriolar) Sodium nitroprusside (arteriolar + venular)
  • 5. Need for life-style changes: •Weight loss/control •Restricted sodium intake •Increasing aerobic exercise •Moderating alcohol consumption These changes in life-style may be sufficient to control hypertension in early stage I They also facilitate pharmacological treatment
  • 6. Diuretics: •Thiazides, loop diuretics and K+ sparing diuretics They are antihypertensive when given alone Also enhance the efficacy of other antihypertensive agents Exact mechanism not known Initially decrease extracellular volume and enhance Na+ excretion by inhibiting Na+Cl- co-transporter which leads to  in CO
  • 7. Long term therapy- CO and extracellular volume returns to pretreatment value due to compensatory mechanisms but antihypertensive effect persists due to decrease in PVR  in PVR may occur due to direct vasodilatory effect of thiazides or due to their effect on kidney
  • 8. Thiazides should be avoided in patients with concommitant: •Diabetes mellitus •Gout •Hyperlipidaemia •Renal insufficiency
  • 9. High efficacy (ceiling) diuretics •Severe reduction in blood volume & electrolyte imbalance •Strong diuretic •Weak antihypertensive than thiazide diuretics •Indicated in HT when complicated by Chronic renal failure Coexisting CHF Severe edema due to use of potent vasodilators
  • 10. Sympatholytic agents: •Centrally acting:  methyldopa, clonidine • Adrenoceptor blockers • Adrenoceptor blockers •Combined  and  adrenoceptor blockers- labetalol, carvedilol
  • 11. Methyldopa: •It is an analog of DOPA (dihydroxyphenylalanine) •It is a pro drug- metabolized in brain by L-aromatic amino acid decarboxylase in adrenergic neurons to  methyl dopamine and then converted to  methyl norepinephrine • Methyl norepinephrine is stored in the vesicles in place of NE and released in response to stimulus •Acts in the CNS to reduce sympathetic outflow from brain stem
  • 12. •Also, probably acts an an agonist of central presynaptic 2 receptors to reduce central sympathetic outflow •Rapidly absorbed, t½ approximately 2 h •Even after i.v. injection effects starts after a delay of about 6-8 h
  • 13. •Why the delay in action? probably due to time taken for transportation to brain and conversion to methyl NE •ADRs: Sedation, transient Dryness of mouth Parkinsonian signs Hyperprolactenemia leading to gynecomastia or galactorrhoea
  • 14. Clonidine, Guanbenz and Guanfacine: •Stimulate 2A subtype of 2 receptors in the brain stem and reduce the central sympathetic outflow • in plasma concentration of NE correlates with the decrease in BP •Decreased sympathetic outflow also reduces cardiac output & HR •In supine position, when the sympathetic tone to vasculature is low, the effect is mainly by reducing HR and stroke volume
  • 15. •In upright position, the vasculature tone is high and effect is mainly by reducing the PVR •Since they block peripheral vasoconstriction, postural hypotension may occur
  • 16. ADRs: •Sedation •Xerostomia •Dryness of eye, nasal mucosa •Parotid swelling •Postural hypotension •Erectile dysfunction •Bradycardia, sinus arrest, AV block •Rebound hypertension
  • 17. Guanadrel: •Exogenous false neurotransmitter •Actively transported to adrenergic neuron by NET (NE transporter) •Previously NET was known as Uptake 1 •Stored in adrenergic neurons where it is concentrated in storage vesicles and replaces NE •Released in place of NE and acts as false neurotransmitter •It has no activity on adrenergic receptors
  • 18. •This inhibits the functioning of peripheral adrenergic neurons •Antihypertensive effect is achieved by reduction in PVR •Postural hypotension
  • 19. -Adrenergic blockers: •Decrease HR, output and stroke volume (1) •Inhibit renin release from JG apparatus (1) •Block -receptors of peripheral blood vessels so they constrict (2) •PVR increases initially but gradually returns to pretreatment values or less •Those crossing the BBB also reduce central sympathetic tone
  • 20. •Do not cause retention of salt and water •Often combined with diuretics- additive effect •Highly preferred drugs for hypertensive patients with complications like angina, MI or CHF
  • 21. -Adrenoceptor blockers produce: •Decreased myocardial contraction & cardiac output (1) •Decreased renin secretion (1) •Decreased central sympathetic activity (Presynaptic 2 effect)
  • 22. All -adrenoceptor blockers produce: •Reduced exercise tolerance •Mild chronic fatigue •Sedation •Increased airway resistance •Bradycardia •Sleep disturbances-  melatonin release
  • 23. •All -adrenoceptor blockers initially produce vasoconstriction by blocking vascular -receptors that relax vascular smooth muscles •This vasoconstriction disappears after some time (adaptability ?)
  • 24. -Adrenoceptor blockers with intrinsic sympathomimetic activity: Advantages: •Less bradycardia & myocardial suppression- useful in patients having low cardiac reserve •Less likely rebound hypertension •Less worsening of lipid profile •Less effect on exercise tolerance
  • 25. β-Adrenoceptor blockers with intrinsic activity: • Oxeprenolol • Pindolol • Penbutolol • Acebutolol
  • 26. Nebivolol: 1 selective antagonist •Promotes vasodilation due to  production of NO in arterial smooth muscle •Has antioxidant properties also
  • 27. 1-Adrenoceptor blockers: •Block 1-adrenoceptors on smooth muscles of arterioles •Reduce arteriolar resistance and increase venous capacitance •Reflex increase in HR and plasma renin activity •Return to normal during long term therapy •Postural hypotension may occur depending on plasma volume
  • 28. •Reduce total plasma concentration of triglycerides and LDL •Increase plasma levels of HDL- beneficial effect •Effect on lipids persists even when combined with diuretics •Preferred in hypertensive patients with BPH
  • 29. Combined  and  adrenoceptor blockers: •Labetalol and carvedilol •Labetalol is a mixture of four stereoisomers- one isomer is  blocker like prazosin, another is a non- selective  blocker with partial agonist activity like pindolol •Other two isomers are inactive •Carvedilol is a  receptor antagonist with 1 receptor blocking activity •Pheochromocytoma
  • 30. Vasodilators: Hydralazine: Directly relaxes the arteriolar smooth muscle Mechanism uncertain Does not relax venous smooth muscle Compensatory reflex increase in sympathetic outflow Increase in HR, cardiac output, plasma renin activity and fluid retention Selective decrease in vascular resistance in coronary, cerebral and renal vascular beds Postural hypotension- uncommon because it does not dilate veins
  • 31. ADRs: •Extension of pharmacological effects: headache, flushing, hypotension, palpitation, tachycardia, dizziness, nausea •Can precipitate angina or MI due to increased myocardial O2 demand •Immunological reactions- drug induced lupus syndrome, serum sickness, hemolytic anemia •Pyridoxine responsive polyneuropathy- probably because hydralazine combines with pyridoxine to form hydrazone
  • 32. Minoxidil: •Converted in liver to active form- minoxidil N-O sulphate •Produces arteriolar vasodilation •No effect on venous capacitance vessels •Causes increase in cardiac output •Blood flow to skin, skeletal muscles, GIT and heart is increased •Dilates renal artery, nett effect depends on hypotension and extent of dilatation
  • 33. •Potent stimulator of renin secretion- by increasing sympathetic outflow and effecting renal regulation of renin release •Minoxidil sulphate opens ATP-modulated K+ channels •K+ efflux occurs, cell is hyperpolarized
  • 34. May precipitate severe bradycardia/sinus arrest Hepatotoxicity- Coombs test (antiglobulin) necessary because autoantibodies are produced against Rh antigen Preferred drug for treatment of hypertension during pregnancy
  • 35. ADRs: •CVS: same as hydralazine •Hypertrichosis: (abnormal hair growth in the body) may occur Uses: •Severe hypertension- should never be given alone; always with a diuretic to prevent fluid retention and a sympatholytic drug to control reflex CVS changes •Baldness- topical
  • 36. Diazoxide: •Chemically related to thiazide diuretics but has no diuretic activity •Instead causes retention of sodium and water •Acts by opening K+ channels in arteriolar smooth muscle cells •No effect on venules •Causes hyperglycemia •Used for short term treatment of hypertensive emergencies •Often combined with a diuretic and a  blocker
  • 37. Fenoldopam: •Agonist of dopamine D1 receptors •Causes dilatation of arterioles and natriuresis •Oral bioavailability is poor •t½ approx. 5 min •Onset of action is rapid •Increases renal output, creatinine clearance and sodium excretion so concomitant use of diuretic or  blocker is not required •ADRs: reflex tachycardia, headache, flushing •Increases intraocular pressure so should be avoided in glaucoma
  • 38. Sodium nitroprusside: •Releases NO which dilates the blood vessels •Mechanism of NO release not known but mimics endogenous NO release by vascular endothelial cells •No development of tolerance (it occurs to nitroglycerine) •Dilates both arterioles and venules •CO falls due to venous pooling and reduction in PVR •Plasma renin activity increases •Unlike arteriolar dilators hydralazine, minoxidil and diazoxide, it causes only modest increase in HR and reduces cardiac O2 demand
  • 39. •Used to treat hypertensive emergencies, aortic dissection, controlled hypotension during anesthesia •Effect of light on drug
  • 40. Toxicity: •Headache, nausea, vomiting-disappear after the drug is discontinued •Cyanide or thiocyanate accumulation •Thiocyanate toxicity- psychosis, disorientation and convulsions •Methemoglobinaemia- due to cyanide
  • 41. •Administration of sodium thiosulfate and hydroxycobalamine •Sodium thiosulfate- acts as a sulfur donor and facilitates metabolism of thiocyanates •Hydrocobalamine- combines with cyanide ion to form non-toxic cyanocobalamine
  • 42. Pregnancy •If taken before pregnancy, most anti-HTN can be continued except ACE inhibitors and angiotensin II receptor blockers. •Methyldopa is most widely used for hypertension during pregnancy. •Beta-blockers are not recommended early in pregnancy.
  • 43. Drugs to be avoided for treatment of hypertension associated with other diseases: Pregnancy ACEI, ARBs, -blockers, diuretics Diabetes mellitus IIDDM) Diuretics, -blockers Angina pectoris Vasodilators Bronchial asthma -blockers Peripheral vascular disease -blockers CHF CCBs except amlodipine,  and -blockers